Censa Pharmaceuticals Inc.

PTC Therapeutics, Inc. sees a year full of regulatory milestones ahead in 2024 following its biologics license application for Upstaza, which could become the first gene therapy delivered directly in

Rare disease-focused PTC Therapeutics, Inc. unveiled Phase III data for its phenylketonuria (PKU) candidate sepiapterin (PTC923) on 17 May that looks capable of positioning the oral synthetic drug t

PTC Therapeutics, Inc. CEO Stuart Peltz told Scrip that with $1.1bn in the bank the company has never been better capitalized to fund its pipeline of rare disease drug candidates. And with royaltie

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker . Roche Pays Vividion $135m Up Front In